2022 Medicine Grand Rounds | Radiotherapy for Renal Cell Carcinoma - Renaissance of An Overlooked Approach

Duarte, CA US
March 1, 2022

Renal cell carcinoma (RCC) has previously been thought of as a radioresistant disease. Until recently, the application of radiation treatment has been largely palliative. Previously there was a paucity of therapy available for RCC. Now there are novel modalities such as stereotactic body radiation therapy (SBRT), which makes it easier to treat. It is essential to stay abreast of such important updates, in order to achieve and deliver appropriate care, in an effort to improve patient quality of life. 

Target Audience

Medical oncologists, urologists and radiation oncologists. 

Learning Objectives

  • Outline the appropriate settings in which to use radiotherapy in renal cell carcinoma (RCC).
  • Review the definitions of oligoprogressive disease.
  • Examine which systemic therapy strategies best synergize with radiotherapy in RCC.
  • Discuss emerging trials that will shape the use of RCC and SBRT in concert.
  • Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
     
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this 2022 Medicine Grand Rounds | Radiotherapy for Renal Cell Carcinoma - Renaissance of An Overlooked Approach for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Activity opens: 
03/01/2022
Activity expires: 
03/04/2022
Event starts: 
03/01/2022 - 12:00pm PST
Event ends: 
03/01/2022 - 1:00pm PST
City of Hope
1500 E Duarte Rd
Duarte, CA 91010
United States

Virtual Meeting- Zoom

Shankar Siva, PhD, MBBS, FRANZCR   Radiation Oncologist, Head of SABR Service; Peter MacCallum Cancer Centre, Melbourne Australia

Dr. Siva has indicated that he receives Grant/Research Support from RefleXion Medical, and Varian Industries; and is On the Speakers Bureau for AstraZeneca.

 

ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: City of Hope designates this live webinar for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The following credit type(s) are being offered for this course:

 AMA PRA Category 1 Credit™  1.0

The following may apply AMA PRA Category 1 Credit™ for license renewal:

Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.

Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this 2022 Medicine Grand Rounds | Radiotherapy for Renal Cell Carcinoma - Renaissance of An Overlooked Approach for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Please login or register to take this activity.